Skip to main content
Caplight Logo









Hasten Biopharmaceutical Co., Ltd.

Hasten Biopharmaceutical Co., Ltd.

Private
HefeiHealthcare & Life Scienceshttps://hastenpharma.com/

Last Round

Series A

Apr 20, 2023

Total Funding Raised

$315M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Hasten Biopharmaceutical Co., Ltd. is a biopharmaceutical company that integrates research, development, production, and commercialization of therapeutics for chronic and critical care diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalpharmaceutical commercializationdrug licensingchronic disease treatmentpharma in-licensingmarket accesscardiovascular medicinemetabolic diseaserespiratory healthpain managementchina pharma marketpharma asset acquisitionbiotech platformpharma distribution

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hasten Biopharmaceutical Co., Ltd. Comparables

Compare Hasten Biopharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.

Hasten Biopharmaceutical Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nuance Pharma
80%
China Medical System Holdings Limited
77%
Shanghai Pioneer Holding Ltd
77%

Hasten Biopharmaceutical Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 20, 2023

Key People

Founding team and executive leadership

Summer XIA Shaofei

Chief Executive Officer

Executive Team

Hasten Biopharmaceutical Co., Ltd. Investors

Notable investors and investment history

Hasten Biopharmaceutical Co., Ltd. investors
InvestorRounds
CBC GroupSeries A
Mubadala Investment CompanySeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 82% MoM.

  • Jul 14, 2025

    Grew 39% QoQ, from 33 to 46 employees.

Hasten Biopharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hasten Biopharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hasten Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersHefei
Employee Range36
Year Founded2020
Last FundingApr 20, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?